Conclusion:
This study confirms the relative frequency of cardiothyrotoxcosis, the proportionally weak place of Basedow disease among hyperthyroidysm causes and the involvement of associated cardiac disease and higher age in cardiothyrotoxicosis.
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Philippe Charron (1), Domitille D'Alançon (2), Uzma Aslam (3), Perry Elliott (4), Hugo Katus (5), Jens Mogensen (6), Lorenzo Monserrat (7), Ygal Pinto (8), Cecilia Trovati (9), Eloisa Arbustini (9 Heidelberg university, Heidelberg, Cardiology departement, Elka, A Coruna Hospital, A Caoruna, Cardiology departement, Amsterdam, Cardiology departement, Pavia, Italie Context: Dilated Cardiomyopathy (DCM) is familial in at least 30% of cases, usually with autosomal dominant inheritance, and underlying genes/ mutations are increasingly identified. Familial DCM is characterized by agerelated penetrance, that means that the cardiac expression of the disease is usually absent for a long period and progressively appears with advanced age, usually after 20 years of age.
Aim: Study the impact of ACE inhibitors (ACEi) in subjects who carry a mutation (leading to a genetic form of heart failure) but have not yet developed DCM (cardiac expression).
Design: This is a multicentre European double-blind randomized and controlled trial with perindopril or placebo in the context of a European consortium "INHERITANCE" (FP7 European Union, HEALTH-2009-2.4.2-3, Grant agreement n°241924). The PRECARDIA trial was recently approved by the Head of medicines Agencies in Europe (HMA) and by AFSSAPS in France. We plan to enroll 200 participants from 7 European centres/countries. Follow-up duration is 3 years after inclusion. Primary Endpoint is a composite end-point: occurrence of DCM or deterioration of LV end diastolic diameter/ volume or Ejection fraction (echocardiographic or magnetic resonance imaging). Secondary Endpoints are related to the evolution of other echocardiographic parameters or hormonal biomarkers (including Mid-Regional proAdrenomedullin).
Expected results:
If the hypothesis is confirmed, and as a consequence, the knowledge derived from basic research (genes identification in DCM) will be translated into clinical practice (early identification of subjects at high risk of developing heart failure through predictive genetic testing) with the development of new therapeutic management (early ACEi) that will help to decrease the morbidity and mortality associated with the disease. This will constitute a paradigm of the development of preventive medicine thanks to the development of genetics in the cardiovascular field. Objectives: We sought to analyze B-type natriuretic peptide (BNP)/troponin I (TnI) ratio and TnI kinetics to differentiate apical ballooning syndrome (ABS) from acute coronary syndrome (ACS).
Methods:
In 62 ABS, TnI and BNP measurements were collected prospectively and compared to 90 patients with anterior ST-segment elevation myocardial infarctions (STEMI) (n=47) and anterior non-STEMI (n=43).
Results:
In case of persistent ST-segment elevation, BNP/TnI ratio above 165 can identify ABS with accuracy (sensitivity: 95%, specificity: 98%). In the absence of persistent ST-segment elevation, a ratio above 515 can identify ABS (sensitivity: 57%, specificity: 86%). Decreasing TnI profile was found more in ABS than in ACS. TnI peak occurred earlier in ABS than in ACS. A normal TnI on patient admission may exclude ABS.
Conclusions:
Analysis of BNP and TnI provides a simple, non-invasive method to differentiate ABS from ACS.
